These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. Saich R; Chapman R World J Gastroenterol; 2008 Jan; 14(3):331-7. PubMed ID: 18200656 [TBL] [Abstract][Full Text] [Related]
49. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Singh S; Khanna S; Pardi DS; Loftus EV; Talwalkar JA Inflamm Bowel Dis; 2013 Jul; 19(8):1631-8. PubMed ID: 23665966 [TBL] [Abstract][Full Text] [Related]
50. Prevention of cancer in IBD - a balancing act. Mill J; Lawrance IC Minerva Gastroenterol Dietol; 2013 Sep; 59(3):261-72. PubMed ID: 23867946 [TBL] [Abstract][Full Text] [Related]
51. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Itzkowitz SH; Harpaz N Gastroenterology; 2004 May; 126(6):1634-48. PubMed ID: 15168373 [TBL] [Abstract][Full Text] [Related]
52. Advances in the Diagnosis and Management of Colonic Dysplasia in Patients With Inflammatory Bowel Disease. Cohen-Mekelburg S; Schneider Y; Gold S; Scherl E; Steinlauf A Gastroenterol Hepatol (N Y); 2017 Jun; 13(6):357-362. PubMed ID: 28690452 [TBL] [Abstract][Full Text] [Related]
53. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Jess T; Loftus EV; Velayos FS; Winther KV; Tremaine WJ; Zinsmeister AR; Scott Harmsen W; Langholz E; Binder V; Munkholm P; Sandborn WJ Am J Gastroenterol; 2007 Apr; 102(4):829-36. PubMed ID: 17222314 [TBL] [Abstract][Full Text] [Related]
54. No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases. Mahmoud R; Shah SC; Ten Hove JR; Torres J; Mooiweer E; Castaneda D; Glass J; Elman J; Kumar A; Axelrad J; Ullman T; Colombel JF; Oldenburg B; Itzkowitz SH; Gastroenterology; 2019 Apr; 156(5):1333-1344.e3. PubMed ID: 30529584 [TBL] [Abstract][Full Text] [Related]
56. Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis. Navaneethan U; Kochhar G; Venkatesh PG; Bennett AE; Rizk M; Shen B; Kiran RP J Crohns Colitis; 2013 Dec; 7(12):974-81. PubMed ID: 23523416 [TBL] [Abstract][Full Text] [Related]
57. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173 [TBL] [Abstract][Full Text] [Related]
58. Optimizing the quality of endoscopy in inflammatory bowel disease: focus on surveillance and management of colorectal dysplasia using interactive image- and video-based teaching. Kaltenbach TR; Soetikno RM; DeVivo R; Laine LA; Barkun A; McQuaid KR; Gastrointest Endosc; 2017 Dec; 86(6):1107-1117.e1. PubMed ID: 28818507 [TBL] [Abstract][Full Text] [Related]
59. Inflammatory Bowel Disease-related Colorectal Cancer in the Asia-Pacific Region: Past, Present, and Future. Zhiqin W; Palaniappan S; Raja Ali RA Intest Res; 2014 Jul; 12(3):194-204. PubMed ID: 25349593 [TBL] [Abstract][Full Text] [Related]
60. Dysplasia and cancer in inflammatory bowel disease. Basseri RJ; Basseri B; Papadakis KA Expert Rev Gastroenterol Hepatol; 2011 Feb; 5(1):59-66. PubMed ID: 21309672 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]